{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:56:05Z","timestamp":1778853365090,"version":"3.51.4"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment outcomes for patients with peripheral T-cell lymphomas (PTCLs) and advanced-stage cutaneous T-cell lymphomas (CTCLs) remain poor. The past few years have witnessed an explosion in our understanding of the genetics of these diverse malignancies. Many subtypes harbor highly recurrent mutations, including single-nucleotide variants, insertions\/deletions, and chromosomal rearrangements, that affect T-cell receptor signaling, costimulatory molecules, JAK\/STAT and phosphatidylinositol 3-kinase pathways, transcription factors, and epigenetic modifiers. An important subset of these mutations is included within commercially available, multigene panels and, in rare circumstances, indicate therapeutic targets. However, current preclinical and clinical evidence suggests that only a minority of mutations identified in TCLs indicate biologic dependence. With a few exceptions that we highlight, mutations identified in TCLs should not be routinely used to select targeted therapies outside of a clinical trial. Participation in trials and publication of both positive and negative results remain the most important mechanisms for improving patient outcomes.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.63","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Challenges and implications of genomics for T-cell lymphomas"],"prefix":"10.1182","volume":"2018","author":[{"given":"Eric D.","family":"Jacobsen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and"},{"name":"Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019111522325190500_B1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","article-title":"Receptor-type tyrosine-protein phosphatase kappa directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111522325190500_B2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.celrep.2016.09.018","article-title":"Insights into the pathogenesis of anaplastic large-cell lymphoma through genome-wide DNA methylation profiling","volume":"17","author":"Hassler","year":"2016","journal-title":"Cell Rep"},{"issue":"9","key":"2019111522325190500_B3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2019111522325190500_B4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"8","key":"2019111522325190500_B5","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1172\/JCI92026","article-title":"Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis","volume":"127","author":"Zang","year":"2017","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111522325190500_B6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/leu.2014.50","article-title":"Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway","volume":"28","author":"Piccaluga","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2019111522325190500_B7","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/nm.2966","article-title":"PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas","volume":"18","author":"Laimer","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"2019111522325190500_B8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1470-2045(05)70213-8","article-title":"Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified","volume":"6","author":"Piccaluga","year":"2005","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111522325190500_B9","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111522325190500_B10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2019111522325190500_B11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The genetic basis of hepatosplenic T-cell lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"2019111522325190500_B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","article-title":"Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma","volume":"131","author":"Kataoka","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2019111522325190500_B13","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"7607","key":"2019111522325190500_B14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2019111522325190500_B15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2019111522325190500_B16","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2","volume":"214","author":"Moffitt","year":"2017","journal-title":"J Exp Med"},{"issue":"2","key":"2019111522325190500_B17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"2019111522325190500_B18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2019111522325190500_B19","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111522325190500_B20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111522325190500_B21","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/blood-2017-11-764357","article-title":"Novel insights into the pathogenesis of T-cell lymphomas","volume":"131","author":"Van Arnam","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019111522325190500_B22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","article-title":"Genetic landscape and classification of peripheral T cell lymphomas","volume":"19","author":"Sandell","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2019111522325190500_B23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2019111522325190500_B24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw248","article-title":"T-cell lymphoma: recent advances in characterization and new opportunities for treatment","volume":"109","author":"Casulo","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019111522325190500_B25","first-page":"417","article-title":"Genetic landscape of adult T-cell leukemia\/lymphoma [in Japanese]","volume":"57","author":"Kataoka","year":"2016","journal-title":"Rinsho Ketsueki"},{"issue":"6","key":"2019111522325190500_B26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"2019111522325190500_B27","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0b013e3182991415","article-title":"ITK\/SYK translocation in angioimmunoblastic T-cell lymphoma","volume":"37","author":"Attygalle","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2019111522325190500_B28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma [published correction appears in Cancer Cell. 2015;27(5):744]","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"issue":"13","key":"2019111522325190500_B29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"issue":"3","key":"2019111522325190500_B30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"issue":"13","key":"2019111522325190500_B31","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111522325190500_B32","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/10428194.2014.941835","article-title":"Imatinib mesylate lacks efficacy in relapsed\/refractory peripheral T cell lymphoma","volume":"56","author":"Jacobsen","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"11-12","key":"2019111522325190500_B33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gad.307504.117","article-title":"JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias","volume":"32","author":"Kim","year":"2018","journal-title":"Genes Dev"},{"issue":"2","key":"2019111522325190500_B34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J Exp Med"},{"issue":"11","key":"2019111522325190500_B35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111522325190500_B36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"2019111522325190500_B37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice [published correction appears in Cancer Cell. 2016;30(1):183]","volume":"29","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"issue":"8","key":"2019111522325190500_B38","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"7683","key":"2019111522325190500_B39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"5","key":"2019111522325190500_B40","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma","volume":"207","author":"Pechloff","year":"2010","journal-title":"J Exp Med"},{"issue":"9","key":"2019111522325190500_B41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/2159-8290.CD-15-1297","article-title":"Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma","volume":"6","author":"Mishra","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2019111522325190500_B42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"issue":"20","key":"2019111522325190500_B43","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111522325190500_B44","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111522325190500_B45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.13170","article-title":"Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma","volume":"168","author":"Cheminant","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111522325190500_B46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111522325190500_B47","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/blood-2012-02-414441","article-title":"TBL1XR1\/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/63\/1251326\/hem01808.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/63\/1251326\/hem01808.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T05:09:28Z","timestamp":1573880968000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/63\/277559\/Challenges-and-implications-of-genomics-for-Tcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.63","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}